Comparison of the toxicities of cisplatin and a new cisplatin-procaine complex to rat renal cortical slices

被引:21
作者
Zhang, JG
Esposito, M
Cafaggi, S
Lindup, WE
机构
[1] UNIV LIVERPOOL,DEPT PHARMACOL & THERAPEUT,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND
[2] IST NAZL RIC CANC,SERV FARMACOL TOSSICOL,I-16132 GENOA,ITALY
[3] UNIV GENOA,IST ANAL & TECNOL FARMACEUT,GENOA,ITALY
来源
HUMAN & EXPERIMENTAL TOXICOLOGY | 1996年 / 15卷 / 01期
基金
英国惠康基金;
关键词
cisplatin; cisplatin-procaine complex; nephrotoxicity; lipid peroxidation; GSH depletion;
D O I
10.1177/096032719601500111
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
1 Procaine has previously been shown to diminish the nephrotoxicity of cisplatin and the nephrotoxic effects of cisplatin and a new cisplatin complex (cis-diamminechloro- [2-(diethylamino) ethyl-4-aminobenzoate, N-4]-chlorideplatinum (II) monohydrochloride monohydrate; DPR), that contains procaine hydrochloride were compared with rat renal cortical slices. 2 Cisplatin at 1 mM caused toxicity to the slices, as shown by an increase in the leakage of aspartate aminotransferase and lactate dehydrogenase from the slices into the incubation medium and a decrease in the reduction of a tetrazolium dye (MTT assay). Addition of procaine (1 mM) protected against cisplatin-induced toxicity. DPR either at 1 mM or at 4 mM had no effect either on the enzyme leakage or MTT reduction by the renal slices, but DPR at 10 mM produced a similar magnitude of enzyme leakage to cisplatin (1 mM). 3 DPR loweredthe concentration of ATP and glutathione (GSH) in the slices but was less potent than cisplatin. Thiobarbituric acid reactive substances, indicators of lipid peroxidation, released into the medium were increased by the highest concentration of DPR (10 mM), which suggests that DPR has the potential to cause oxidative stress. 4 The results suggest that DPR was far less toxic than either cisplatin alone or a mixture of cisplatin and procaine.
引用
收藏
页码:59 / 63
页数:5
相关论文
共 19 条
[1]   NEWER INSIGHTS INTO CISPLATIN NEPHROTOXICITY [J].
ANAND, AJ ;
BASHEY, B .
ANNALS OF PHARMACOTHERAPY, 1993, 27 (12) :1519-1525
[2]  
CAFAGGI S, 1992, ANTICANCER RES, V12, P2285
[3]  
CHOIE DD, 1981, LAB INVEST, V44, P397
[4]   THERAPEUTIC EFFICACY OF VARIOUS DOSAGES AND MODALITIES OF ADMINISTRATION [J].
DELENA, M ;
LORUSSO, V ;
PARADISO, A ;
TOMMASI, S .
INORGANICA CHIMICA ACTA-BIOINORGANIC CHEMISTRY, 1987, 137 (1-2) :91-97
[5]   PARA-AMINOBENZOIC ACID SUPPRESSION OF CIS-DIAMMINEDICHLOROPLATINUM(II) NEPHROTOXICITY [J].
ESPOSITO, M ;
VANNOZZI, MO ;
VIALE, M ;
FULCO, RA ;
COLLECCHI, P ;
MERLO, F ;
DECIAN, F ;
ZICCA, A ;
CADONI, A ;
POIRIER, MC .
CARCINOGENESIS, 1993, 14 (12) :2595-2599
[6]   IMPROVED THERAPEUTIC INDEX OF CISPLATIN BY PROCAINE HYDROCHLORIDE [J].
ESPOSITO, M ;
FULCO, RA ;
COLLECCHI, P ;
ZICCA, A ;
CADONI, A ;
MERLO, F ;
ROSSO, R ;
SOBRERO, A .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (08) :677-684
[7]   ASSAY OF PICOMOLE AMOUNTS OF ATP, ADP, AND AMP USING LUCIFERASE ENZYME-SYSTEM [J].
KIMMICH, GA ;
RANDLES, J ;
BRAND, JS .
ANALYTICAL BIOCHEMISTRY, 1975, 69 (01) :187-206
[9]  
PHILLIPPY BQ, 1994, BIOTECHNIQUES, V16, P596
[10]  
SLEIJFER DT, 1985, PHARM WEEKBLAD SCI E, V7, P227